The North America Chemiluminescence Immunoassay Market is experiencing robust growth due to advancements in diagnostics and increasing healthcare expenditure. The market size was valued at USD 2580 Million in 2025 and is expected to reach USD 5850 Million by 2035, growing at a CAGR of 7.8% from 2024 to 2035.
The economic impact of tariffs on "North America Chemiluminescence Immunoassay Market".
Market Growth Drivers
Rising Prevalence of Chronic Diseases: The increasing incidence of chronic diseases such as cancer, diabetes, and infectious diseases is significantly driving the demand for chemiluminescence immunoassay (CLIA) products in North America. According to Roche Diagnostics, there has been a notable uptick in diagnostic tests usage due to the rising burden of chronic health conditions. This has led hospitals and laboratories to adopt advanced immunoassay systems to provide fast and accurate diagnostic results, further fueling market growth.
Technological Advancements and New Product Launches: Continuous technological progression in CLIA platforms and the introduction of automated and high-throughput analyzers are major drivers. Companies like Abbott Laboratories have invested in R&D and launched the Architect i2000SR, which has improved test speed and accuracy while reducing manual errors. These developments cater to the growing demand for precise diagnostic solutions in large healthcare settings, boosting market expansion.
Market Trends
Shift Towards Point-of-Care Testing: There is a noticeable shift towards point-of-care testing and decentralized diagnostics in North America. Companies such as Siemens Healthineers have introduced portable CLIA analyzers that can deliver rapid results at the patient’s bedside or in remote locations, addressing the need for faster decision-making and efficient patient management.
Integration of Artificial Intelligence (AI) in Immunoassay Workflows: The adoption of AI-driven analytics and automation is streamlining chemiluminescence immunoassay workflows. Beckman Coulter has integrated AI algorithms into their latest immunoassay systems, enabling laboratories to increase throughput and accuracy while minimizing human intervention, resulting in improved operational efficiency and error reduction.
Market Opportunity
Expansion in Personalized Medicine: Increasing focus on personalized medicine and biomarker-based diagnostics offers significant growth potential. Companies like Thermo Fisher Scientific are developing CLIA assays tailored for targeted therapies, enhancing patient outcomes.
Growth in Home-Based Testing: The rising acceptance of self-testing and remote diagnostics is enabling manufacturers to launch home-compatible CLIA kits, as seen in recent initiatives by QuidelOrtho, unlocking a new revenue stream and expanding market reach.
North America Chemiluminescence Immunoassay Market Revenue (USD Million), 2020-2035
The chart shows a consistent upward trajectory in the North America Chemiluminescence Immunoassay Market from 2020 to 2035. Starting at USD 1480 Million in 2020, the market experiences steady annual growth, reaching USD 2580 Million by 2025 and projecting up to USD 5850 Million in 2035. The CAGR of 7.8% is driven by increasing diagnostic awareness, rising prevalence of chronic diseases, and ongoing technological advancements. Strategic collaborations, product launches, and regulatory support have further boosted market performance. This positive trend is expected to continue as healthcare infrastructure and diagnostic accessibility improve across North America.
North America Chemiluminescence Immunoassay Market by Regional Share (%), 2025
The pie chart for 2025 illustrates the dominance of the United States, accounting for 78% of the chemiluminescence immunoassay market, owing to extensive healthcare infrastructure and higher diagnostic test adoption rates. Canada follows with 15%, leveraging its investments in healthcare modernization and preventive diagnostics programs. Mexico holds 5% as awareness and infrastructure improve, while the rest of North America regions share the remaining 2%. These regional dynamics are expected to remain stable, with emerging healthcare investments in Canada and Mexico gradually increasing their market shares in the long term.
Recent Developments in North America CLIA Market
In May 2024, Abbott Laboratories launched its next-generation Alinity i chemiluminescence immunoassay system across North America, specifically targeting high-volume laboratories and offering improved throughput, automation, and user-friendly interfaces. This product aims to reduce turnaround time and improve diagnostic accuracy for critical diseases.
In June 2024, Siemens Healthineers received FDA clearance for its new Atellica CH Analyzer, a chemiluminescence platform optimized for both centralized and decentralized laboratory settings. The analyzer incorporates enhanced automation features and supports a broader menu of infectious disease and hormone assays.
In April 2024, Bio-Rad Laboratories announced a strategic collaboration with leading healthcare providers to co-develop novel CLIA tests for cancer biomarkers. This partnership focuses on accelerating the availability of multiplex chemiluminescence panels, with pilot implementation scheduled in major US hospital networks throughout the latter half of 2024.
Press Releases